⌘K
Loading ticker…
As of 2026-08-24, ADC Therapeutics SA (ADCT) has a 3-month relative strength percentile of 3 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 26. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.1%, relative volume 0.48×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ADCT is in a stage 4 downtrend, week 11. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -15.1% / -68.8%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
ADCT is held by 5 ETFs as of May 2026. Top owner: VTWO at 0.01% weight, $2M notional. Top 3 carry $3M.
Held by 6 ETFs · $3M across latest filings · largest weight 0.06% (VFMO).
Top 5 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.01% | $2M | — |
| VFMO | 0.06% | $1M | −0.03 pp |
| VTWG | 0.02% | $324K | — |
| VTHRVanguard Russell 3000 ETF | 0.00% | $32K | — |
| MSSM | 0.00% | $9K | — |
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ADCT Jan avg: 26.93% median: 17.67% win: 75% σ: 45.38% n: 4 2022-04-12 → 2026-07-31 | ADCT Feb avg: 10.90% median: 9.17% win: 75% σ: 34.68% n: 4 2022-04-12 → 2026-07-31 | ADCT Mar avg: -20.32% median: -14.21% win: 0% σ: 17.95% n: 4 2022-04-12 → 2026-07-31 | ADCT Apr avg: -2.11% median: -0.51% win: 40% σ: 4.84% n: 5 2022-04-12 → 2026-07-31 | ADCT May avg: 12.61% median: -10.05% win: 40% σ: 62.20% n: 5 2022-04-12 → 2026-07-31 | ADCT Jun avg: -16.39% median: -8.51% win: 20% σ: 31.33% n: 5 2022-04-12 → 2026-07-31 | ADCT Jul avg: -6.28% median: -1.87% win: 40% σ: 14.67% n: 5 2022-04-12 → 2026-07-31 | ADCT Aug avg: -7.17% median: -10.31% win: 25% σ: 12.82% n: 4 2022-04-12 → 2026-07-31 (current) | ADCT Sep avg: -3.91% median: -8.31% win: 50% σ: 28.45% n: 4 2022-04-12 → 2026-07-31 | ADCT Oct avg: -7.21% median: -9.18% win: 25% σ: 13.89% n: 4 2022-04-12 → 2026-07-31 | ADCT Nov avg: -4.19% median: -8.89% win: 25% σ: 16.30% n: 4 2022-04-12 → 2026-07-31 | ADCT Dec avg: 17.31% median: -6.42% win: 50% σ: 56.16% n: 4 2022-04-12 → 2026-07-31 |